AR061306A1 - Compuestos de pirrolidin-3-1l-piperidina como agonistas de receptores muscarinicos - Google Patents

Compuestos de pirrolidin-3-1l-piperidina como agonistas de receptores muscarinicos

Info

Publication number
AR061306A1
AR061306A1 ARP070102508A ARP070102508A AR061306A1 AR 061306 A1 AR061306 A1 AR 061306A1 AR P070102508 A ARP070102508 A AR P070102508A AR P070102508 A ARP070102508 A AR P070102508A AR 061306 A1 AR061306 A1 AR 061306A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
heteroaryl
heterocycloalkyl
aryl
Prior art date
Application number
ARP070102508A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38801729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061306(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR061306A1 publication Critical patent/AR061306A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas, procesos e intermediarios. Son utiles en la terapia, en particular en el manejo del dolor, Alzheimer, esquizofrenia. Reivindicacion 1: Un compuesto de formula 1, una sal aceptable para uso farmacéutico de dicho compuesto, un diastereomero, un enantiomero o una mezcla de dicho compuesto donde R1 se selecciona independientemente de hidrogeno, halogeno, alquilo C1-6, alquenilo C2-6, -CN, -C(=O)-OR, -C(=O)-NR2, hidroxi, alcoxi C1-6, trifluormetilo, FCH2-, F2CH- , CHF2O-, CF3O-, arilo C6-10 y heteroarilo C2-9; R2 se selecciona de hidrogeno, alquilo C1-6, alquenilo C2-6, alcoxi C1-6, alquilamino C1-6, di-alquilamino C1-6, arilo C6-10, ariloxi C6-10; heteroarilo C2-9, heteroariloxi C2-9, heterocicloalquiloxi C3-5, heterocicloalquilo C3-9, aril C6-10-alcoxi C1-3, aril C6-10-alquilo C1-3, heteroaril C2-9-alcoxi C1-3, heteroaril C2-9-alquilo C1-3, heterocicloalquil C3-6-alcoxi C1-3, heterocicloalquil C3-6-alquilo C1-3, cicloalquilo C3-9, cicloalquiloxi C3- 6 y cicloalquil C3-6-alquilo C1-3, cicloalquil C3-6-alcoxi C1-3, donde dicho alquilo C1-6, alquenilo C2-6, alcoxi C1-6, alquilamino C1-6, di-alquilamino C1-6, ariIo C6-10, ariloxi C6-10; heteroarilo C2-9, heteroariloxi C2-9, heterocicloalquiloxi C3- 5, heterocicloalquilo C3-9, aril C6-10-alcoxi C1-3, aril C6-10-alquilo C1-3, heteroaril C2-9-alcoxi C1-3, heteroaril C2-9-alquilo C1-3, heterocicloalquil C3-6-alcoxi C1-3, heterocicloalquil C3-6-alquilo C1-3, cicloalquilo C3-9, cicloalquiloxi C3-6 y cicloalquil C3-6-alquilo C1-3, cicloalquil C3-6-alcoxi C1-3, está opcionalmente sustituido con uno o varios grupos seleccionados de -CN, -SR, -OR, -O(CH2)p-OR, R, -C(=O)-R, -CO2R, -SO2R, -SO2NR2, halogeno, -NO2, -NR2, -(CH2)pNR2 y -C(=O)-NR2; G1, G2, G3 y G4 se seleccionan independientemente de H y metilo; o dos de G1, G2, G3 y G4 están unidos para formar un alquileno C1-4, y los otros dos se seleccionan independientemente de H y metilo; n es 1, 2, 3 o 4; cada R es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6 o alquilo C1-6 halogenado; y X, Y y Z se seleccionan independientemente de C(=O), NH, N-CH3, N, C, CH2 y CH, donde al menos uno de X, Y y Z se selecciona de NH, N-CH3 y N; donde como máximo uno de X, Y y Z es C(=O); y donde Z no es C(=O).
ARP070102508A 2006-06-09 2007-06-08 Compuestos de pirrolidin-3-1l-piperidina como agonistas de receptores muscarinicos AR061306A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81220806P 2006-06-09 2006-06-09

Publications (1)

Publication Number Publication Date
AR061306A1 true AR061306A1 (es) 2008-08-20

Family

ID=38801729

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102508A AR061306A1 (es) 2006-06-09 2007-06-08 Compuestos de pirrolidin-3-1l-piperidina como agonistas de receptores muscarinicos

Country Status (18)

Country Link
US (1) US20100173935A1 (es)
EP (1) EP2035412A4 (es)
JP (1) JP2009539833A (es)
KR (1) KR20090016636A (es)
CN (1) CN101501024A (es)
AR (1) AR061306A1 (es)
AU (1) AU2007256014B2 (es)
BR (1) BRPI0712415A2 (es)
CA (1) CA2654147A1 (es)
EC (1) ECSP088967A (es)
IL (1) IL195427A0 (es)
MX (1) MX2008015155A (es)
NO (1) NO20085271L (es)
RU (1) RU2008147543A (es)
TW (1) TW200815405A (es)
UY (1) UY30393A1 (es)
WO (1) WO2007142585A1 (es)
ZA (1) ZA200809976B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
RU2488585C2 (ru) 2007-08-31 2013-07-27 Пэдью Фарма Л.П. Замещенные пиперидиновые соединения хиноксалинового типа и их применение
US20090221567A1 (en) * 2008-02-28 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177
US20090221642A1 (en) * 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
DK2324013T6 (en) 2008-07-21 2014-12-15 Purdue Pharma Lp Substituted bridged piperidine compounds of quinoxalintype and uses thereof
GB0817982D0 (en) * 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
WO2012020813A1 (ja) * 2010-08-10 2012-02-16 大日本住友製薬株式会社 縮環ピロリジン誘導体
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
JP2015083543A (ja) * 2012-02-14 2015-04-30 大日本住友製薬株式会社 新規縮環ピロリジン誘導体
US20140171466A1 (en) * 2012-08-14 2014-06-19 Regents Of The University Of Minnesota Pain management in sickle cell anemia
JP6204476B2 (ja) * 2012-09-18 2017-09-27 ヘプタレス セラピューティックス リミテッド ムスカリンｍ１受容体作動薬としての二環式アザ化合物
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5524326A (en) * 1993-01-21 1996-06-11 Markowitz; Eli Interactive game between pet and owner
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
WO1999032481A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
ATE275141T1 (de) * 1999-10-13 2004-09-15 Banyu Pharma Co Ltd Substituierte imidazolin-derivate
WO2002085890A1 (fr) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Derives de benzimidazolone
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US7279490B2 (en) * 2002-06-17 2007-10-09 Merck & Co, Inc. Ophthalmic compositions for treating ocular hypertension
JPWO2004069828A1 (ja) * 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 ピペリジン化合物およびその医薬用途
GEP20084421B (en) * 2004-05-12 2008-07-10 Pfizer Prod Inc Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
EP1753429A1 (en) * 2004-05-28 2007-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
TW200815351A (en) * 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
US20090221567A1 (en) * 2008-02-28 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177
US20090221642A1 (en) * 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300

Also Published As

Publication number Publication date
MX2008015155A (es) 2008-12-12
ECSP088967A (es) 2009-01-30
BRPI0712415A2 (pt) 2012-09-04
CN101501024A (zh) 2009-08-05
KR20090016636A (ko) 2009-02-16
US20100173935A1 (en) 2010-07-08
JP2009539833A (ja) 2009-11-19
EP2035412A1 (en) 2009-03-18
AU2007256014B2 (en) 2011-06-30
TW200815405A (en) 2008-04-01
ZA200809976B (en) 2011-04-28
UY30393A1 (es) 2009-04-30
EP2035412A4 (en) 2011-02-16
WO2007142585A1 (en) 2007-12-13
CA2654147A1 (en) 2007-12-13
IL195427A0 (en) 2009-08-03
AU2007256014A1 (en) 2007-12-13
RU2008147543A (ru) 2010-07-20
NO20085271L (no) 2009-01-06

Similar Documents

Publication Publication Date Title
AR061306A1 (es) Compuestos de pirrolidin-3-1l-piperidina como agonistas de receptores muscarinicos
AR061305A1 (es) Agonistas de receptores muscarinicos
RU2010110036A (ru) Производные пиперидина в качестве агонистов мускариновых рецепторов
ES2604947T3 (es) Compuestos de pirazin-2-il-piridin-2-il-amina y pirazin-2-il-pirimidin-4-il-amina y su uso
AR060729A1 (es) Compuestos agonistas de los receptores muscarinicos
RU2426729C2 (ru) Ингибиторы митотического кинезина и способы их использования
RU2010135253A (ru) Агонисты мускариновых рецепторов, композиции и способы лечения с их применением и способы их получения 177
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
ATE360004T1 (de) Imidazopyridine, -pyrimidine und -triazine als gaba-a alpha 5 rezeptor subtyp liganden zur verbesserung kognitiver eigenschaften
AR053699A1 (es) Derivados de tetrahidro-1h-pirido[4,3-b]indoles como ligandos de receptores cb1
ME00555B (me) Derivati tropana i njihova primj ena
NI200600257A (es) Nuevos compuestos.
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR033295A1 (es) Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
AR020551A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos.
RU2010117156A (ru) Гетероциклические соединения в качестве антагонистов crth2 рецептора
CO5080744A1 (es) Ligandos de alta afinidad para el receptor de nociceptina orl-1
AR074352A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica.
AR048232A1 (es) Piperidinilcarbonil- pirrolidinas y su uso como agonistas de melanocortina cr4
AR038341A1 (es) Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR073922A1 (es) 2- oxoquinoxalinas como bloqueadores de los canales de sodio tardios
PE20061156A1 (es) Derivados de benzamida como agentes inhibidores del transportador de glicina
RU2009120229A (ru) Производные хинуклидинола в качестве антагонистов мускариновых рецепторов

Legal Events

Date Code Title Description
FB Suspension of granting procedure